The Current Ratio as of September 2024 (TTM) for Novo Nordisk A/S (NVO) is 0.94

According to Novo Nordisk A/S’s latest financial reports and current stock price. The company's current Current Ratio is 0.94. This represents a change of 14.68% compared to the average of 0.82 of the last 4 quarters.

Novo Nordisk A/S (NVO) Historical Current Ratio (quarterly & annually)

How has NVO Current Ratio performed in the past?

The mean historical Current Ratio of Novo Nordisk A/S over the last ten years is 1.09. The current 0.94 Current Ratio has changed 8.55% with respect to the historical average. Over the past ten years (40 quarters), NVO's Current Ratio was at its highest in in the December 2014 quarter at 1.37. The Current Ratio was at its lowest in in the March 2024 quarter at 0.70.

Novo Nordisk A/S (NVO) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Novo Nordisk A/S Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Novo Nordisk A/S (NVO) Average Current Ratio

How has NVO Current Ratio performed in the past?

The current Current Ratio of Novo Nordisk A/S (NVO) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Novo Nordisk A/S (NVO) Current Ratio vs. Peers

How is NVO’s Current Ratio compared to its peers?

Novo Nordisk A/S’s Current Ratio is less than Regeneron Pharmaceuticals, Inc. (5.44), less than CRISPR Therapeutics AG (15.73), less than Sarepta Therapeutics, Inc. (3.90), less than Intellia Therapeutics, Inc. (7.21), less than Moderna, Inc. (4.09), less than CureVac N.V. (2.29), less than Novavax, Inc. (1.04), less than CohBar, Inc. (4.16), less than Reata Pharmaceuticals, Inc. (3.21), less than BioNTech SE (7.54), less than Ginkgo Bioworks Holdings, Inc. (4.71), less than Vertex Pharmaceuticals Incorporated (2.52), less than BioMarin Pharmaceutical Inc. (3.05), less than Seagen Inc. (2.67), less than Alnylam Pharmaceuticals, Inc. (3.01), less than Madrigal Pharmaceuticals, Inc. (8.72), less than Intercept Pharmaceuticals, Inc. (4.22), less than TG Therapeutics, Inc. (3.58), less than Terns Pharmaceuticals, Inc. (21.02), less than Hepion Pharmaceuticals, Inc. (5.62),

Build a custom stock screener for Novo Nordisk A/S (NVO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Novo Nordisk A/S using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Novo Nordisk A/S (NVO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Novo Nordisk A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.